Diagnostics
-
Redefining Survivorship: Proactive Strategies for Preventing Chronic Breast Cancer-Related Lymphedema
March is Lymphedema Awareness Month, and today there are more options than ever to help prevent this challenging and all too common complication associated with breast cancer treatment.
-
Improving Communication Between Patients and Providers
Sarah Shillington, Chief Customer Officer notes how Artera’s omnichannel platform works.
-
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
-
How Access to Capital Benefits Radiology and Radiologists
Private equity is a way to help achieve scale. Groups that use scale to better serve the stakeholders that matter most, including radiologists, hospitals, referring physicians and—most importantly—patients, will be best positioned to not just survive, but thrive.
-
MedCity Influencers, Artificial Intelligence
Mitotic Counting Reimagined: When AI Meets the Microscope
The shift towards digital pathology has marked a significant advancement in breast cancer diagnosis. High-resolution digital imaging of slides provides pathologists with an unprecedentedly clear and expansive view of tissue samples for their analysis.
-
EU Orders Grail Sale; Illumina Continues Appeals But Plans for Multiple Outcomes
European Union regulators ordered Illumina to divest Grail. Illumina is appealing antitrust findings in Europe and the U.S., but the DNA sequencing giant revealed that divesting all or part of Grail is an option even if it wins both legal challenges.
-
Liquid Biopsy Startup Precede Sets Out to Make Precision Medicine More Precise
Precede Biosciences’ liquid biopsy platform yields insight into the genes and pathways in diseased tissue. Based on Dana-Farber Cancer Institute research, the startup aims to support biopharma drug R&D as it also develops the technology for clinical care applications.
-
Invitae’s First of Its Kind Cancer Test Receives FDA Marketing Authorization
The FDA awarded marketing authorization for a new Invitae test that uses next-generation sequencing to assess multiple genes to identify variants indicating a person’s predisposition for certain cancers. The regulatory action creates a new regulatory classification making Invitae’s test the predicate device for future cancer tests.
-
How Genome Sequencing Can Broaden the Scope of Newborn Screening
Standard newborn screening can detect dozens of inherited diseases, but genomics technology enables testing for hundreds of them. A North Carolina program evaluating the feasibility of bringing genomics to newborn screening is expanding with an initial goal of testing 5,000 babies in the next year.
-
How Corti’s AI System Assists Clinicians
Andreas Cleve, Corti CEO, talks on how his company handles AI responsibly with its customers.
-
Quest Expands in Cancer Testing With $300M Haystack Oncology Acquisition
Quest Diagnostics is acquiring liquid biopsy company Haystack Oncology. The startup’s technology is used for identifying cancer patients who need adjuvant therapy.
-
StartUPDATES: New Developments from Healthcare Startups
Check out news from BioMEMS Diagnostics, Rx Redefined, Ferrum Health and Avanlee Care.
-
More Talent and Technology Offer Solutions for Medical Laboratory Staffing Shortages
Process improvement and advanced technology can also help relieve the staffing burden that medical laboratories are facing.
-
Thermo Fisher bets big on blood cancer, immune diagnostics with $2.6B Binding Site buyout
Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.
-
Report: Cancer deaths are down but pancreatic cancer is growing, racial disparities persist
Targeted drugs and immunotherapies are among the advances that contribute to declines in incidence and deaths from non-small cell lung cancer, according to the Annual Report to the Nation on the Status of Cancer. But the trends are on the rise for some other cancers and racial disparities persist, highlighting the need to better understand these differences.
-
Owkin’s AI solutions for breast and colorectal cancer receive European approval
The breast cancer solution will help determine which patients would benefit from targeted therapies and which patients could avoid chemotherapy. Meanwhile, the colorectal solution will be able to match patients with the most effective treatment sooner.